AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36917194 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Chronotype
Number of subjects: 0
Study 36917194 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36917429 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (180 mg or 360 mg) delivered subcutaneously via on-body injector (OBI)
Number of subjects: 46
Study 36917429 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Injection Assessment Questionnaire (SIAQ)
Number of subjects: 46
Study 36917429 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical remission (CD Activity Index < 150)
Number of subjects: 46
Study 36917429 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability assessment of OBI
Number of subjects: 46
Study 36917429 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site reactions
Number of subjects: 46
Study 36917429 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 46
Study 36917461 — intervention group
Group type: EXPERIMENTAL
Intervention: Accompanying dyspnoea
Number of subjects: 6045
Study 36917461 — intervention group
Group type: COMPARATOR
Intervention: No accompanying dyspnoea
Number of subjects: 6045
Study 36917484 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention with two additional individual visits for health and psychological education
Number of subjects: 123
Study 36917484 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient consultations (Control Group)
Number of subjects: 123
Study 36917566 — intervention group
Group type: EXPERIMENTAL
Intervention: 170J BTE waveform (SHOCK A)
Number of subjects: 49
Study 36917566 — intervention group
Group type: COMPARATOR
Intervention: 150J BTE waveform (SHOCK B)
Number of subjects: 49
Study 36917566 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated 170J BTE waveform (SHOCK A)
Number of subjects: 49
Study 36917566 — intervention group
Group type: COMPARATOR
Intervention: Attenuated 150J BTE waveform (SHOCK B)
Number of subjects: 49
Study 36917566 — intervention group
Group type: EXPERIMENTAL
Intervention: SHOCK A
Number of subjects: 49
Study 36917566 — intervention group
Group type: COMPARATOR
Intervention: SHOCK B
Number of subjects: 49
Study 36917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during cMDA
Number of subjects: 74
Study 36917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude towards deworming and perceived ability to participate in cMDA
Number of subjects: 74
Study 36917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Caste (SC/ST)
Number of subjects: 74
Study 36917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation
Number of subjects: 74
Study 36917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Caste and family type
Number of subjects: 74
Study 36917758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen 5 mg once daily for 3 years
Number of subjects: 500
Study 36917758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 36918123 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis combined with occlusal stabilization splint
Number of subjects: 40
Study 36918157 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating room temperature of 24°C (75°F)
Number of subjects: 5217
Study 36918157 — intervention group
Group type: COMPARATOR
Intervention: Standard care operating room temperature of 20°C (67°F)
Number of subjects: 5217
Study 36918215 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatry ankle duplex scan (PAD-scan) monophasic or biphasic with adverse features
Number of subjects: 123
Study 36918215 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe brachial pressure index of ≤0.2
Number of subjects: 123
Study 36918215 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous pressure of oxygen of ≤20 mm Hg
Number of subjects: 123
Study 36918215 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic waveforms on PAD-scan
Number of subjects: 123
Study 36918215 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with non-adverse features on PAD-scan
Number of subjects: 123
Study 36918228 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment for FM
Number of subjects: 51
Study 36918228 — intervention group
Group type: COMPARATOR
Intervention: FM individuals
Number of subjects: 51
Study 36918228 — intervention group
Group type: COMPARATOR
Intervention: FM-PS cases
Number of subjects: 51
Study 36918236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose, 1000 mg
Number of subjects: 0
Study 36918236 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FS), ca. 200 mg every day
Number of subjects: 0
Study 36918234 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen anti-inflammatory diet (GrAID)
Number of subjects: 255
Study 36918234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocolonic-delivered oral vitamin B
Number of subjects: 255
Study 36918234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 36918264 — intervention group
Group type: EXPERIMENTAL
Intervention: Error disclosure by NICU professionals
Number of subjects: 1019
Study 36918264 — intervention group
Group type: COMPARATOR
Intervention: Nighttime discovery of error
Number of subjects: 1019
Study 36918264 — intervention group
Group type: COMPARATOR
Intervention: Milder consequence of error
Number of subjects: 1019
Study 36918264 — intervention group
Group type: COMPARATOR
Intervention: Shorter interval between admission and error
Number of subjects: 1019
Study 36918264 — intervention group
Group type: COMPARATOR
Intervention: Error type and fewer beds
Number of subjects: 1019
Study 36918264 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-disclosure
Number of subjects: 1019
Study 36918342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of procollagen
Number of subjects: 166
Study 36918342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of osteopontin
Number of subjects: 166
Study 36918342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of IL-19
Number of subjects: 166
Study 36918342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of IL-33
Number of subjects: 166
Study 36918342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of TNFα
Number of subjects: 166
Study 36918342 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of IL-6
Number of subjects: 166
Study 36918342 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of IL-20
Number of subjects: 166
Study 36918342 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of TGFβ
Number of subjects: 166
Study 36918342 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of IL-1β
Number of subjects: 166
Study 36918384 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care competence (PCC)
Number of subjects: 0
Study 36918384 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care climate (PCQ-S)
Number of subjects: 0
Study 36918384 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PCC and PCQ-S total scores
Number of subjects: 0
Study 36918384 — intervention group
Group type: COMPARATOR
Intervention: Nurses' educational levels
Number of subjects: 0
Study 36918384 — intervention group
Group type: COMPARATOR
Intervention: Nurses' individual characteristics (age, work experience)
Number of subjects: 0
Study 36918388 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects on GFR slope
Number of subjects: 200
Study 36918388 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects on UACR change
Number of subjects: 200
Study 36918388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment effects on UACR change and GFR slope
Number of subjects: 200
Study 36918416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protein-carbohydrate (PRO-CHO)
Number of subjects: 25
Study 36918416 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-only (CHO)
Number of subjects: 25
Study 36918464 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (RAPN)
Number of subjects: 395
Study 36918464 — intervention group
Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 395
Study 36918550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg QD on Day 1-5
Number of subjects: 15
Study 36918550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg QD with dorzagliatin 75 mg BID on Day 6-10
Number of subjects: 15
Study 36918550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin 75 mg BID alone on Day 11-15
Number of subjects: 15
Study 36918846 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 409
Study 36918892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed collagen type II (HC-II)
Number of subjects: 160
Study 36918892 — intervention group
Group type: EXPERIMENTAL
Intervention: Essence of chicken with added HC-II (EC-HC-II)
Number of subjects: 160
Study 36918892 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine HCl
Number of subjects: 160
Study 36918892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 36918896 — intervention group
Group type: EXPERIMENTAL
Intervention: GFC-NHS-POx patch
Number of subjects: 20
Study 36918896 — intervention group
Group type: EXPERIMENTAL
Intervention: ORC-PLGA-NHS-POx: NU-POx patch
Number of subjects: 20
Study 36918896 — intervention group
Group type: COMPARATOR
Intervention: TachoSil
Number of subjects: 20
Study 36918924 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Number of subjects: 1800
Study 36918924 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 1800
Study 36918949 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 79
Study 36918949 — intervention group
Group type: COMPARATOR
Intervention: High-load resistance training (HL-RT) combined with AT
Number of subjects: 79
Study 36918949 — intervention group
Group type: COMPARATOR
Intervention: Low-load resistance training (LL-RT) combined with AT
Number of subjects: 79
Study 36918949 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RT) combined with AT
Number of subjects: 79
Study 36918956 — intervention group
Group type: EXPERIMENTAL
Intervention: PICU Up! intervention (multifaceted early mobility intervention)
Number of subjects: 1440
Study 36918956 — intervention group
Group type: EXPERIMENTAL
Intervention: PICU Up! intervention
Number of subjects: 1440
Study 36918956 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1440
Study 36919122 — intervention group
Group type: EXPERIMENTAL
Intervention: 4×4 high-intensity interval training (HIIT) protocol
Number of subjects: 12
Study 36919122 — intervention group
Group type: EXPERIMENTAL
Intervention: 10×1 high-intensity interval training (HIIT) protocol
Number of subjects: 12
Study 36919122 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both HIIT protocols
Number of subjects: 12
Study 36919398 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 730357 (oral treatment)
Number of subjects: 274
Study 36919514 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH; 20 mg)
Number of subjects: 60
Study 36919514 — intervention group
Group type: EXPERIMENTAL
Intervention: Slot machine gambling (Slots)
Number of subjects: 60
Study 36919514 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (HAL; 3-mg) or fluphenazine (FLU; 3-mg)
Number of subjects: 60
Study 36919608 — intervention group
Group type: EXPERIMENTAL
Intervention: lonafarnib therapy
Number of subjects: 0
Study 36919608 — intervention group
Group type: EXPERIMENTAL
Intervention: progerin-targeted treatment
Number of subjects: 0
Study 36919800 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex communication skills training program for physicians providing advanced cancer care
Number of subjects: 0
Study 36919879 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36920122 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pain (upregulated genes)
Number of subjects: 40
Study 36920122 — intervention group
Group type: COMPARATOR
Intervention: Patients without pain (downregulated genes)
Number of subjects: 40
Study 36920122 — intervention group
Group type: EXPERIMENTAL
Intervention: Key genes of interest (MMP8, PCSK9, DEFA3)
Number of subjects: 40
Study 36920158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health application based on Roy's Adaptation Model, used from 32nd-34th gestational weeks to sixth week postpartum
Number of subjects: 62
Study 36920158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile health application)
Number of subjects: 62
Study 36920397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg oral twice daily)
Number of subjects: 80
Study 36920397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36920397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 80
Study 36920449 — intervention group
Group type: EXPERIMENTAL
Intervention: Res-Up! (CAP)
Number of subjects: 0
Study 36920449 — intervention group
Group type: EXPERIMENTAL
Intervention: REMOTION (COMP)
Number of subjects: 0
Study 36920449 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 0
Study 36920460 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month nonlinear aerobic exercise program with 3 weekly sessions
Number of subjects: 209
Study 36920460 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 209
Study 36920465 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone and remote sensor data (Android smartphone, Withings Steel HR+, Body+, BPM Connect+)
Number of subjects: 38
Study 36920465 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task regression models for FSHD Clinical Score and TUG test
Number of subjects: 38
Study 36920465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitask regression model for estimating both clinical assessments simultaneously
Number of subjects: 38
Study 36920652 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 combined with reintroduced chemotherapy (carboplatin/cisplatin and etoposide)
Number of subjects: 0
Study 36920652 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 0
Study 36920745 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate (high dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Number of subjects: 60
Study 36920745 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate (low dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Number of subjects: 60
Study 36920745 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate (both groups)
Number of subjects: 60
Study 36920755 — intervention group
Group type: EXPERIMENTAL
Intervention: Inaxaplin
Number of subjects: 16
Study 36920756 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system of insulin delivery
Number of subjects: 102
Study 36920756 — intervention group
Group type: COMPARATOR
Intervention: Standard care (insulin pump or multiple daily injections plus continuous glucose monitor)
Number of subjects: 102
Study 36920756 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study 36920778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (250 mg, loading dose of 500 mg at baseline and week 2, administered subcutaneously every 2 weeks)
Number of subjects: 851
Study 36920778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered subcutaneously every 2 weeks)
Number of subjects: 851
Study 36920778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Number of subjects: 851
Study 36921081 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor
Number of subjects: 0
Study 36921494 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib plus cetuximab plus 5-FU/LV
Number of subjects: 164
Study 36921494 — intervention group
Group type: EXPERIMENTAL
Intervention: capecitabine plus trastuzumab plus pertuzumab
Number of subjects: 164
Study 36921494 — intervention group
Group type: EXPERIMENTAL
Intervention: cobimetinib plus atezolizumab
Number of subjects: 164
Study 36921494 — intervention group
Group type: COMPARATOR
Intervention: fluoropyrimidine plus bevacizumab
Number of subjects: 164
Study 36921506 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized cognitive stimulation program for 10 weeks
Number of subjects: 337
Study 36921515 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-criteria diagnostic model (lack of prior hallucinations, lack of movement disorders tremor excluded, no cognitive fluctuations, and ≥75 years of age at diagnosis)
Number of subjects: 79
Study 36921515 — intervention group
Group type: EXPERIMENTAL
Intervention: 3/4 criteria diagnostic model
Number of subjects: 79
Study 36921766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus stereotactic ablative radiotherapy (SABR)
Number of subjects: 106
Study 36921766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential fractions (50 Gy/4f) to the lung
Number of subjects: 106
Study 36921766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-targeted groups
Number of subjects: 106
Study 36921804 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy U.S.-Style Dietary Pattern (HDP) with unprocessed or processed lean red meats
Number of subjects: 19
Study 36921804 — intervention group
Group type: COMPARATOR
Intervention: Healthy U.S.-Style Dietary Pattern (HDP) without lean red meats
Number of subjects: 19
Study 36921804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from all 3 diet interventions
Number of subjects: 19
Study 36921902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation cookies (LCs) with galactagogues (56.5 g daily for 1 month)
Number of subjects: 176
Study 36921902 — intervention group
Group type: COMPARATOR
Intervention: Conventional cookies (56.5 g daily for 1 month)
Number of subjects: 176
Study 36921902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation cookies (LCs) with galactagogues
Number of subjects: 176
Study 36921902 — intervention group
Group type: COMPARATOR
Intervention: Conventional cookies
Number of subjects: 176
Study 36921903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonemulsified olive oil
Number of subjects: 16
Study 36921903 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified olive oil
Number of subjects: 16
Study 36921903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonemulsified coconut oil
Number of subjects: 16
Study 36921903 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified coconut oil
Number of subjects: 16
Study 36921903 — intervention group
Group type: COMPARATOR
Intervention: All fats tested
Number of subjects: 16
Study 36921943 — intervention group
Group type: EXPERIMENTAL
Intervention: Long COVID group
Number of subjects: 360
Study 36921943 — intervention group
Group type: EXPERIMENTAL
Intervention: Short COVID group
Number of subjects: 360
Study 36921943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 36922042 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR care pathway and cusp overlap technique (COT)
Number of subjects: 400
Study 36922042 — intervention group
Group type: COMPARATOR
Intervention: 4-step COT compliance
Number of subjects: 400
Study 36922046 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip NTR/XTR transcatheter edge-to-edge repair system
Number of subjects: 1041
Study 36922052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical-Electric Thrombectomy
Number of subjects: 0
Study 36922331 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg TID for 2 weeks
Number of subjects: 1258
Study 36922331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258
Study 36922413 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Thera-Band strengthening exercises and scapular stabilization exercises 5 days a week for 8 weeks
Number of subjects: 70
Study 36922413 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 70
Study 36922497 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib monotherapy (C1)
Number of subjects: 47
Study 36922497 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib and dostarlimab (C2)
Number of subjects: 47
Study 36922593 — intervention group
Group type: EXPERIMENTAL
Intervention: Menin inhibitor revumenib
Number of subjects: 0
Study 36922769 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence-enhancing interventions performed monthly for 3 consecutive months for adolescents with VL1 > 1000 copies/ml
Number of subjects: 280
Study 36922769 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 280
Study 36922777 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 µg of vitamin D supplementation
Number of subjects: 2000
Study 36922777 — intervention group
Group type: COMPARATOR
Intervention: 10 µg of vitamin D supplementation
Number of subjects: 2000
Study 36922785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilofexor 100 mg once daily for up to 96 weeks
Number of subjects: 0
Study 36922785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36922785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilofexor 100 mg daily (open-label) after the blinded phase
Number of subjects: 0
Study 36922805 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (41.4 Gy with 23 fractions) with concurrent chemotherapy (albumin-bound paclitaxel, 100 mg/m2) followed by tislelizumab.
Number of subjects: 0
Study 36922813 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program in clinical research (9-month duration)
Number of subjects: 6
Study 36922807 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban interventions in four contiguous neighborhoods
Number of subjects: 0
Study 36922807 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0